In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vifor Fresenius gets ex-US and Japanese rights to Relypsa's hyperkalemia therapy

Executive Summary

Relypsa Inc. licensed Galenica Group's Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive worldwide rights (excluding the US and Japan) to commercialize the hyperkalemia therapy patiromer for oral suspension globally except in the US and Japan.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies